Tegafur,Gimeracil and Oteracil Potassium
- Generic Name
- Tegafur,Gimeracil and Oteracil Potassium
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于不能切除的局部晚期或转移性胃癌。
用于治疗成人胆道癌【日本PMDA已批准；《胆管癌诊断与治疗-外科专家共识》】。
- Associated Conditions
- -
- Associated Therapies
- -
RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2
- Conditions
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT05403242
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
🇨🇳Beijing Friendship Hospital, Beijing, China
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
- Conditions
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 626
- Registration Number
- NCT05144854
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
🇯🇵IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 65
- Registration Number
- NCT05111444
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2021-08-31
- Target Recruit Count
- 210
- Registration Number
- NCT04982939
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
- Conditions
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT04856761
- Locations
- 🇨🇳
Huashan hospital, Shanghai, China
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Quan Wang
- Target Recruit Count
- 37
- Registration Number
- NCT04694183
- Locations
- 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China
ONO-4538 Phase II Rollover Study (ONO-4538-98)
- Conditions
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 59
- Registration Number
- NCT04566380
- Locations
- 🇯🇵
Kanagawa Clinical Site1, Yokohama, Kanagawa, Japan
🇯🇵Tokyo Clinical Site3, Bunkyo-ku, Tokyo, Japan
🇯🇵Chiba Clinical Site2, Chiba, Japan
Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT04217096
- Locations
- 🇨🇳
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University; 270 Dong An Road, Shanghai 200032, China, Shanghai, China
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2024-05-16
- Target Recruit Count
- 55
- Registration Number
- NCT04207918
- Locations
- 🇨🇳
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China
A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04152889
- Locations
- 🇨🇳
Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.